“IMO the worst case scenario is that the FDA ask for more data before making a decision (not disapproval, but delay to get more data points)”

Is there a history of the FDA delaying a BTD response to request more data? And can CYDY submit data from the 2 additional patients to the FDA to support the already filed BTD packet?

These are important questions.